BACKGROUND Evidence is lacking about the effectiveness of risk reduction interventions in patients with asymp-
P rescription of statins to prevent cardiovascular disease (CVD) is mainly a "high-risk" strategy focused on detection and intensive management of risk factors in individuals with a high probability of developing CVD (1) . In the lipid management arena, this approach is grounded in the knowledge that the absolute risk reduction achieved with statin therapy improves with increasing CVD risk (2) .
Detection of asymptomatic peripheral arterial disease (PAD) using the ankle-brachial index (ABI) in screening procedures is a potentially useful strategy to identify candidates for intensive risk-factor management (3) because low ABI values are associated with an increased risk of CVD and total mortality, independent of the CVD risk calculated by the Framingham function (4) . Moreover, ABI measurement is reliable, simple, and inexpensive, and therefore suitable for target-population risk screening (5) .
Unfortunately, the usefulness of this screening remains uncertain (6, 7) , and available guidelines offer heterogeneous recommendations (8) . The American College of Cardiology, American Heart Association, and Inter-Society Consensus for the management of patients with PAD have recommended ABI screening, especially for certain groups of asymptomatic individuals (principally subjects age 50 to 69 years who also have diabetes or smoking history, and all patients age >70 years) (9) . In contrast, the U.S. Preventive Services Task Force recommends against routine ABI screening in asymptomatic adults (8) . One fundamental reason for this uncertainty is the lack of evidence about the effectiveness of risk reduction interventions when asymptomatic PAD is detected (10) .
In this study, we aimed to assess whether statin use was associated with a reduction in incidence of CVD and mortality in individuals with asymptomatic PAD detected by ABI measurement. Ramos et al. The hazard ratios of statin exposure were calculated for outcome events using conditional Cox proportional hazard regression models, and proportionality of hazards assumption was tested.
Additional regression adjustments were performed after PS matching to prevent residual confounding in a sensitivity analysis. Variables not sufficiently balanced after PS matching and those associated with a worse prognosis were also included in the models. 
Ramos et al. Table 2 ).
Baseline characteristics for statin new-users and nonusers before and after PS matching are presented in The complete-case analysis showed no statistical or clinically relevant differences from the hazard ratios obtained in previously described analyses of the multiple imputations dataset (Online Table 3 ). Hazard ratios from the model with additional adjustment for hypertension, hypercholesterolemia, aspirin use, nonstatin lipid-lowering drug use, ABI, and 10-year coronary heart disease risk did not significantly differ from the PS matching model (Online Table 4 ). The hazard ratios obtained when considering statins as a time-varying covariate did not significantly differ from those of the intention-to-treat approach; the relative differences were <10% for all outcomes (Online Table 5 ). We observed no significant increase of adverse events attributable to statins ( Table 2) .
DISCUSSION
To our knowledge, this is the first study to report the association between statins and both MACE and mortality reduction among individuals free of clinical CVD, but with asymptomatic PAD identified by ABI.
This reduction was observed regardless of 10-year CHD risk levels at baseline, which for most participants were well below the treatment threshold according to current prevention guidelines (27) . Values are mean AE SD or n (%). *Calculated for all participants with diabetes mellitus.
ABI ¼ ankle brachial index; ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; CHD ¼ coronary heart disease; COPD ¼ chronic obstructive pulmonary disease; CKD ¼ chronic kidney disease (glomerular filtration rate <60 ml/min/1.73 m 2 ); HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein. be assessed as an additional factor to support statin therapy in patients at low 10-year coronary heart disease risk and with moderate LDL cholesterol blood level (27) . Our results support such a strategy, because most patients in our study meet these characteristics.
Second, and consequently, routine ABI screening for asymptomatic PAD in the targeted population could be a useful strategy (32) to identify candidates for statin therapy, most of whom would not be considered candidates solely on the basis of risk functions (16) . A targeted population ABI screening could detect up to 85% of those individuals with 
CI ¼ confidence interval; HR ¼ hazard ratio; NNT ¼ number needed to treat. The number needed to treat to prevent 1 event over a 5-year follow-up by ankle brachial index (A) and by coronary heart disease risk at baseline (B).
Ramos et al. We also observed no increased risk of cancer or hemorrhagic stroke among statins new-users, which is consistent with previous studies (38, 39) . We cannot discard the possibility that the incidence of diabetes, cancer, or hemorrhagic stroke could increase in this population with longer statin exposure.
STUDY CHARACTERISTICS THAT MERIT CONSIDERATION.
When data are collected in well-designed, quality-assured databases and analyzed using appropriate Table 2 , Online Figure 1 ) and also to those with low ABI in population-based epidemiological studies in the same population (32, 33) . The exception is the proportion of diabetes (twice as high in our study), which is probably due to diabetes guidelines strongly recommending ABI screening (44) . We cannot discard that this might affect our results to some extent, but the general characteristics of our study participants support their representativeness of the asymptomatic PAD population, which provides external validity for targeted population screening (32 
